• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Tendler Craig claimed no ownership of stock in the company (SEC Form 3)

    3/19/25 7:12:21 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HURA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Tendler Craig

    (Last) (First) (Middle)
    10500 UNIVERSITY CENTER DRIVE, SUITE 110

    (Street)
    TAMPA FL 33612

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/10/2025
    3. Issuer Name and Ticker or Trading Symbol
    TuHURA Biosciences, Inc./NV [ HURA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 0(1) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This Form 3 is being filed solely to reflect the reporting person becoming a director, officer or 10% owner of TuHURA Biosciences, Inc.
    Remarks:
    See Exhibit 24 - Power of Attorney.
    /s/ Dan Dearborn as Power of Attorney for Craig Tendler 03/19/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HURA

    DatePrice TargetRatingAnalyst
    3/3/2025$13.00Buy
    H.C. Wainwright
    12/19/2024$11.00Buy
    Rodman & Renshaw
    11/5/2024$15.00Buy
    Maxim Group
    More analyst ratings

    $HURA
    SEC Filings

    View All

    TuHURA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

    4/1/26 8:00:08 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by TuHURA Biosciences Inc.

    10-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

    3/31/26 5:15:26 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by TuHURA Biosciences Inc.

    SCHEDULE 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

    2/17/26 4:18:27 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

    TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's fourth quarter and full year ended December 31, 2025, and provided a corporate update."2025 was a strong year of executing upon our goals, and we continue to move all our programs forward this year. As we progress our clinical development pipeline, we have strategically strengthened our clinical and drug development expertise with Craig Tendler, M.D., providing the strategic and operational services consistent with those o

    4/1/26 7:45:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

    Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than $16 billion in worldwide sales TAMPA, Fla., March 23, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Dr. Craig L. Tendler will provide strat

    3/23/26 7:45:00 AM ET
    $HURA
    $KTRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

    TAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26, 2026, it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the "Listing Rule"). Nasdaq confirmed that for the last 11 consecutive business days, from February 10, 2026, through February 25, 2026, the closing bid price of the Company's common stock has been at $1.00 per share or grea

    2/27/26 7:30:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Tendler Craig

    4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

    2/17/26 4:21:30 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ng George K

    4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

    2/17/26 4:19:47 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Manuso James S J

    4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

    2/17/26 4:17:30 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on TuHURA Biosciences with a new price target

    H.C. Wainwright initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $13.00

    3/3/25 7:23:43 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on TuHURA Biosciences with a new price target

    Rodman & Renshaw initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $11.00

    12/19/24 7:41:52 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on TuHURA Biosciences with a new price target

    Maxim Group initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $15.00

    11/5/24 7:54:57 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Financials

    Live finance-specific insights

    View All

    TuHURA Biosciences Provides Corporate Update Following Recent Financing

    Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) targeting completion of enrollment Q4-2026 A mini KOL symposium held on December 5, 2025, provided the scientific rational for targeting VISTA in AML and the clinical applications in combination with a menin inhibitor in NPM1 mutated relapsed/refractory AML Oral and poster presentations at the recently concluded 57th ASH Annual Meeting showed the Delta Opioid Receptor (DOR) to be a compelling new target as th

    12/11/25 7:30:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

    Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025 MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025 Expanded discovery team for first-in-class immune modulating Antibody Drug or Peptide Conjugate Program TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overco

    4/1/25 8:00:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by TuHURA Biosciences Inc.

    SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

    10/25/24 4:30:14 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TuHURA Biosciences Inc.

    SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

    10/25/24 4:28:34 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TuHURA Biosciences Inc.

    SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

    10/25/24 4:26:02 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Leadership Updates

    Live Leadership Updates

    View All

    TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

    Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) Company's Delta Opioid Receptor (DOR) technology selected for an oral presentation, along with 2 poster presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Orlando, Florida on December 6-9, 2025 TAMPA, Fla., Nov. 14, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing

    11/14/25 7:00:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

    Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Peptide Conjugate (APC) technology platform Inventor of first-in-class spirocyclic DOR agonists as potential analgesics; clinical- stage products licensed to Pfizer Led the benevopran opioid-induced bowel dysfunction program to positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceutic

    4/7/25 8:24:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care